Reduction of skin stress by CBD products: Aiming high above the competition

0
56
Reduction of skin stress by CBD products: Aiming high above the competition


The relationship between stress and skin are further substantiated through clinical observations linking, psychological stress to the onset or aggravation of skin conditions.   (Inflammation & Allergy – Drug Targets, 2014, 13, 177-190)

To mitigate the effects of acute and chronic stress, inflammatory pathways are looked at as upstream targets for technology development. Much of the effect of the inflammatory cascades arise from lipid-like bio-signaling molecules, further sharpening the search for an effective technology development strategy. Cannabinoids fit the bill nicely.       

Leveraging cannabinoids as a hero technology therapeutically is driven out from the discovery of the endocannabinoid system (ECS), which regulates many functions in the human body. Furthermore, the importance of the ECS and the prevalence of cannabinoid receptors (CRs) in the skin (see image below) are implicated in maintaining skin homeostasis. Dysfunction to the ECS system in the skin has been implicated in various skin conditions such as atopic dermatitis (AD), itch, acne, alopecia and hypopigmentation disorders.  (Eur J Pharmacol. 1998;359(1):1–18)  

Cannabinoids have a proven track record for modulating inflammatory pathways and can be added to the arsenal of therapeutics developed to mitigate skin stress. (Pharmaceutics. 2020 Mar; 12(3): 265) This makes them a favorable technology platform strategy as many cannabinoids functionally cross over into multiple biological systems that ultimately involve the skin, thus making them wholistic in application to skin stress and skin recovery

There is a good correlation between in vitro established mechanisms and therapeutic value as it relates to skin stress. For example, acne, itch and melanin deposition studies found that CBD inhibited the actions of several know agonists in each of these areas respectively. (Inflamm Res. 2003; 52:238–245), (Cannabis and Cannabinoid Research (Volume 5, Number 4, 2020)

New brands containing cannabinoids are materializing in every niche of personal care. As a result, there is more pressure for proper compliance, documentation and scientific expertise. Choosing partners that are well versed from a regulatory perspective while being nimble and agile to perform customized, accurate and timely testing with good documentation will provide the confidence and execution you will need for your next launch.

Submit the form to download a free brochure on Eurofins’ CBD testing capabilities.

Disclaimer:

The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsi­bility for the accuracy, completeness and validity of all information included. Cosmetics & Toiletries takes steps to ensure that you will not confuse sponsored content with content produced by Cosmetics & Toiletries and governed by its editorial policy.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here